Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer

Trial Profile

Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Hemay 020 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Tianjin Hemay Biotech
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 27 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top